KPV
Alpha-MSH-derived tripeptide investigated in inflammatory, gut and skin models.
Predominantly preclinical evidenceExplore this ingredient →← All stacks & combinationsINGREDIENT INGREDIENT POPULAR GOALS THE COMMUNITY RATIONALE THE OPEN QUESTION KPV GHK-CU Lab and animal research · KPV alone Regulatory guidance · ingredient safety
Community combination
KPV + GHK-Cu
KPV + GHK-Cu brings together interest in calmer-looking skin, inflammation and tissue repair. Evidence from products applied to the skin cannot automatically be applied to other uses.
Skin & HairImmune & Inflammation
01
THE BUILDING BLOCKS
What’s in it?
GHK-Cu
Copper-binding peptide studied in skin, wound and cellular research.
Limited evidenceExplore this ingredient →The ingredients listed here do not specify a particular product or mixing ratio. Pre-mixed products may differ from the formulations used in research.
02
PEOPLE & EXPERIENCE
Why this combination is discussed
KPV + GHK-Cu brings together interest in calmer-looking skin, inflammation and tissue repair. Evidence from products applied to the skin cannot automatically be applied to other uses.
Skin & HairImmune & Inflammation
This pairing attracts interest around skin care, inflammation and tissue repair.
Studies of products applied to the skin do not tell us how an injected combination would behave. Whether the ingredients can be mixed also needs separate testing.
Community experience can explain why a pairing has become popular. It cannot show whether the ingredients work better together or whether a mixed product is stable, accurately dosed or safe.
03
THE REASON FOR INTEREST
Why people combine them
This pairing attracts interest around skin care, inflammation and tissue repair.
How their research overlaps
Studies of products applied to the skin do not tell us how an injected combination would behave. Whether the ingredients can be mixed also needs separate testing.
The individual profiles explain each ingredient’s potential benefits and research. Even when their effects seem complementary, studies are needed to find out whether using them together adds a benefit.
04
No human combination study found in this searchWHAT THE RESEARCH CAN SUPPORT
Evidence for this combination
We did not find a human study testing these ingredients together in our targeted search. That leaves their combined benefits and safety uncertain; it does not show that the pairing is ineffective.
KPV research in experimental gut models does not tell us how a skin blend would work. Products applied to the skin and injected products need separate evidence.
Explore the sources below ↓05
RESEARCH & COMMUNITY CONTEXT
Doses & duration
Start with each ingredient—not an invented combined dose
No validated combined starting dose exists. The cards below preserve the practical structure people look for while keeping each ingredient’s reported pattern separate.
Anecdotal / unvalidated
- Starting point discussed
- 200 mcg once daily is a commonly published anecdotal starting amount for oral or subcutaneous use; topical products use formulation-specific concentrations and are not comparable.
- Duration / cycle
- Community descriptions commonly use daily dosing for four to eight weeks, sometimes moving within a 200–500 mcg daily range.
- Continuation / break
- A pause and review after a short course is often discussed, but no maintenance dose or evidence-based break interval has been validated.
Anecdotal injectable pattern · topical products vary
- Starting point discussed
- Topical use is usually discussed by product strength and directions. Injectable discussions often begin around 1 mg per day, but no human dose-finding study validates that starting amount.
- Duration / cycle
- Four-to-eight-week topical or injected courses are commonly described. Formulation, route and absorbed exposure are not interchangeable.
- Continuation / break
- Intermittent topical use is widely discussed; there is no validated injectable maintenance dose, cycle or break interval.
Using two ingredients in the same period and mixing them in one vial or syringe are different questions. Separate schedules cannot establish compatibility, interactions or a safe combined total.
06
WHAT REMAINS UNCERTAIN
Safety & uncertainties
- The combination needs its own safety research, including possible interactions and side effects.
- What a product contains, how it is made and how it is used all matter. Products sold under the same name may differ.
- A clinician can assess how existing medicines or health conditions affect the risks. These pages provide general information, not personal treatment advice.
07
FOLLOW THE EVIDENCE
Sources & search record
Last source check: 14 September 2026
Each link explains what it covers: the combination itself, an individual ingredient or safety information. A trial record and a paper can describe the same study.
Dalmasso et al., 2008 — PepT1-mediated KPV uptake ↗
Early research on KPV and intestinal inflammation. It did not test KPV with another peptide in people.
FDA: peptide compounding safety concerns ↗
Safety information about individual ingredients, rather than the combination. This is US guidance, not a statement of UK legal status.
About this search
We used targeted web searches for ingredient pairs, including searches focused on PubMed and ClinicalTrials.gov. We followed relevant papers, research reviews and FDA safety information, checking whether the ingredients were actually given together and how they were used. Some full papers were unavailable, so we relied on their published summaries. Web searches can miss studies: this was a targeted source check, not an exhaustive or systematic review, a clinical assessment or a review of UK regulation. The links below let you explore further; search results are not evidence on their own.
Search terms used
- "KPV" "GHK-Cu" study trial
- "KPV" "GHK-Cu" site:pubmed.ncbi.nlm.nih.gov
- site:clinicaltrials.gov "KPV" "GHK-Cu"
Search for these ingredients together:
Studies may use different names for the same ingredient. The search terms above show which alternatives we checked. Community experiences can explain interest in a stack, but we did not count anecdotes or seller claims as clinical studies.